Capturing the real-world benefit of residual β-cell function during clinically important time-periods in established Type 1 diabetes.

Despite only being prescribed to individuals who are more likely to spend time in hypoglycaemia, mean time spent <3.9 mmol/L overnight was reduced by CGM, although this did not reach statistical significance.

also in 111,027 other papers